VolitionRx Unveils Groundbreaking Research on Lung Cancer Risk Stratification at ELCC

VolitionRx Announces Significant Findings at ELCC 2026

HENDERSON, Nev., March 26, 2026 /PRNewswire/ -- This week, VolitionRx Limited (NYSE AMERICAN: VNRX), a leading multinational company focused on epigenetics, presented a groundbreaking abstract at the European Lung Cancer Conference (ELCC) in Copenhagen, Denmark. The discussion centered around the application of their Nu.Q® Cancer assays in enhancing the management of lung cancer patients, providing promising insights that could revolutionize patient care.

Key Findings and Implications

The presentation featured significant results encapsulated in Poster 244P titled "Preoperative Nucleosome Liquid Biopsy for Prognostic Stratification in Lung Cancer With Treatment Correlation." Joint lead author, Dr. Pei-Hsing Chen from the National Taiwan University Hospital, highlighted that measuring preoperative H3K27Me3-nucleosomes via Volition's innovative blood test can effectively stratify Non-Small Cell Lung Cancer (NSCLC) patients by identifying who would benefit most from rigorous follow-up and potential secondary treatments.

Dr. Chen stated, "Our research indicates that high levels of H3K27Me3-nucleosomes correlate with poorer recurrence-free survival and overall survival rates in patients, while lower levels signify significantly improved outcomes. This crucial differentiation can aid in quickly identifying micro-metastatic diseases, thus allowing clinicians to make more informed treatment decisions, especially for high-risk patients."

This innovative approach underscores the utility of Volition's Nu.Q® Cancer technology in clinical settings, offering healthcare professionals enhanced tools for monitoring and treatment decisions along the patient’s journey through lung cancer management.

Advancements in Patient Care

Dr. Andrew Retter, a Medical Consultant at Volition, reinforced that the findings represent a leap forward in precision medicine for lung cancer management. The Nu.Q® Cancer tests not only enable better prognostic assessments but also ensure that tailored treatment options can be employed based on individual patient profiles. "Our collaborations in Taiwan and Lyon have consistently showed that utilizing the Nu.Q® technology aids in enhancing the chain of treatment decisions, ultimately aiming to improve patient survival rates and quality of life," he remarked.

The studies and clinical trials reinforce the promise of Volition's approach in enriching clinical prognostication tools that cater to patient-centered care.

Future Directions for Volition

VolitionRx remains committed to harnessing its epigenetic technologies to improve lives across the globe. They are on the brink of integrating the Nu.Q® assays into routine clinical practice — a milestone tied to the company’s core mission of saving lives through earlier and more accurate disease detection.

As Volition continues to expand its research and development capabilities, significant efforts are being made to ensure their blood tests are not only effective but also easily deployable within clinical practices. Their mission extends beyond lung cancer to a broad spectrum of diseases related to NETosis and various cancers, demonstrating the versatility of their innovative diagnostic technologies.

Conclusion

With the promising findings from the ELCC, VolitionRx’s commitment to advancing epigenetics-based solutions for better patient outcomes in lung cancer and beyond continues to gain momentum. The integration of Nu.Q® assays into everyday healthcare may soon change the landscape of how patients navigate their diagnosis and treatment, heralding a new era in personalized medicine.

About VolitionRX
VolitionRX is an innovative company focused on the science of epigenetics, dedicated to improving health outcomes through earlier detection and treatment monitoring. Through their subsidiaries, they are developing cost-effective blood-based tests for various diseases, highlighting their commitment to advancing healthcare and patient quality of life.

For media inquiries, please contact:
Louise Batchelor, Volition
Email: [email protected]
Phone: +44 (0)7557 774620

Disclaimer

This article may contain forward-looking statements that involve risks and uncertainties relating to Volition's future performance. Please refer to the full disclaimer regarding these statements and other relevant information available through official channels.